Evaluation of the profiles of CB1 cannabinoid receptor signalling bias using joint kinetic modelling

被引:12
|
作者
Zhu, Xiao [1 ]
Finlay, David B. [2 ,3 ]
Glass, Michelle [2 ,3 ]
Duffull, Stephen B. [1 ]
机构
[1] Univ Otago, Otago Pharmacometr Grp, Sch Pharm, POB 56, Dunedin, New Zealand
[2] Univ Otago, Dept Pharmacol & Toxicol, Dunedin, New Zealand
[3] Univ Auckland, Dept Pharmacol & Clin Pharmacol, Fac Med & Hlth Sci, Auckland, New Zealand
关键词
FUNCTIONAL SELECTIVITY; AGONISM; QUANTIFICATION; PHARMACOLOGY; MECHANISM;
D O I
10.1111/bph.15066
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and Purpose Biased agonism describes the ability of ligands to differentially regulate multiple signalling pathways when coupled to a single receptor. Signalling is affected by rapid agonist-induced receptor internalisation. Hence, the conventional use of equilibrium models may not be optimal, because (i) receptor numbers vary with time and, in addition, (ii) some pathways may show non-monotonic profiles over time. Experimental Approach Data were available from internalisation, cAMP inhibition and phosphorylation of ERK (pERK) of the cannabinoid-1 (CB1) receptor using a concentration series of six CB1 ligands (CP55,940, WIN55,212-2, anandamide, 2-arachidonylglycerol, Delta(9)-tetrahydrocannabinol and BAY59,3074). The joint kinetic model of CB1 signalling was developed to simultaneously describe the time-dependent activities in three signalling pathways. Based on the insights from the kinetic model, fingerprint profiles of CB1 ligand bias were constructed and visualised. Key Results A joint kinetic model was able to capture the signalling profiles across all pathways for the CB1 receptor simultaneously for a system that was not at equilibrium. WIN55,212-2 had a similar pattern as 2-arachidonylglycerol (reference). The other agonists displayed bias towards internalisation compared to cAMP inhibition. However, only Delta(9)-tetrahydrocannabinol and BAY59,3074 demonstrated bias in the pERK-cAMP pathway comparison. Furthermore, all the agonists exhibited little preference between internalisation and pERK. Conclusion and Implications This is the first joint kinetic assessment of biased agonism at a GPCR (e.g. CB1 receptor) under non-equilibrium conditions. Kinetic modelling is a natural method to handle time-varying data when traditional equilibria are not present and enables quantification of ligand bias.
引用
收藏
页码:3449 / 3463
页数:15
相关论文
共 50 条
  • [1] Cannabinoid CB1 and CB2 Receptor Signaling and Bias
    Ibsen, Mikkel Soes
    Connor, Mark
    Glass, Michelle
    CANNABIS AND CANNABINOID RESEARCH, 2017, 2 (01) : 48 - 60
  • [2] CB1 cannabinoid receptor signalling in Parkinson's disease
    Brotchie, JM
    CURRENT OPINION IN PHARMACOLOGY, 2003, 3 (01) : 54 - 61
  • [3] The CB1 cannabinoid receptor in the brain
    Howlett, AC
    NEUROBIOLOGY OF DISEASE, 1998, 5 (06) : 405 - 416
  • [4] Cannabinoid CB1 Receptor Antagonists
    Thomas, Brian F.
    DRUG DEVELOPMENT RESEARCH, 2009, 70 (08) : 525 - 526
  • [5] CB1 cannabinoid receptor ligands
    Thakur, GA
    Nikas, SP
    Makriyannis, A
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2005, 5 (07) : 631 - 640
  • [6] CB1 cannabinoid receptor antagonists
    Barth, F
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 40, 2005, 40 : 103 - 118
  • [7] The Cannabinoid CB1 Receptor in Schizophrenia
    Borgan, Faith
    Kokkinou, Michelle
    Howes, Oliver
    BIOLOGICAL PSYCHIATRY-COGNITIVE NEUROSCIENCE AND NEUROIMAGING, 2021, 6 (06) : 646 - 659
  • [8] Preclinical Evaluation of Neutral Cannabinoid CB1 Receptor Antagonists and Cannabinoid CB1 Receptor Negative Allosteric Modulators for Treating Drug Addiction
    Gardner, Eliot L.
    Bi, Guo-Hua
    Thakur, Ganesh
    Makriyannis, Alexandros
    Seltzman, Herbert H.
    He, Xiang-Hu
    Xi, Zheng-Xiong
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2016, 19 : 152 - 152
  • [9] Cannabinoid Receptor Interacting Protein (CRIP1a) attenuates CB1 signalling
    Hardt, Tricia Ann
    Elphick, Maurice
    Lewis, Deborah L.
    Selley, Dana E.
    FASEB JOURNAL, 2009, 23
  • [10] Voltage dependence of the cannabinoid CB1 receptor
    Goldberger, Esty
    Tauber, Merav
    Ben-Chaim, Yair
    FRONTIERS IN PHARMACOLOGY, 2022, 13